Urenco Annual Report 2022

16. Called up share capital 31/12/22 €m 31/12/21 €m Authorised Ordinary share capital, 240 million ordinary shares of £1 each: ‘A’ ordinary shares 113.0 113.0 ‘B’ ordinary shares 113.0 113.0 ‘C’ ordinary shares 113.0 113.0 339.0 339.0 Issued Allotted, called up and fully paid, 168 million ordinary shares of £1 each: ‘A’ ordinary shares 79.1 79.1 ‘B’ ordinary shares 79.1 79.1 ‘C’ ordinary shares 79.1 79.1 237.3 237.3 The ‘A’, ‘B’ and ‘C’ ordinary shares have identical rights. 17. Retained earnings €m As at 31 December 2020 and 1 January 2021 975.5 Net profit for the year 2021 352.0 Dividends paid (300.0) Actuarial gains on retirement benefit obligation 9.9 Deferred tax on actuarial gains (2.5) Foreign exchange translation differences 63.2 As at 31 December 2021 and 1 January 2022 1,098.1 Net profit for the year 2022 249.3 Dividends paid (300.0) Actuarial gains on retirement benefit assets 2.6 Deferred tax on actuarial gains (0.7) Foreign exchange translation differences (42.7) As at 31 December 2022 1,006.6 The €3.3 million loss in the Hedging reserve (2021: €2.6 million gain) relates to fair value movements recognised on debt instruments that are designated in a hedge relationship. As at 31 December 2022, the Company had distributable reserves available of €974.1 million (2021: €1,069.9 million). Financial statements Notes to the Company Financial Statements continued For the year ended 31 December 2022 178 Urenco Annual report and accounts 2022 Financial statements 03